{
  "format": "listen-step-protocol@1",
  "kind": "module",
  "name": "Mepact-type DOPS/POPC liposomal mifamurtide",
  "tags": [
    "Liposome",
    "Literature recipe"
  ],
  "steps": [],
  "labItems": [
    {
      "id": "component-mepact-dops-popc-liposomal-mifamurtide",
      "kind": "recipe",
      "afterStep": 0,
      "snapshot": {
        "id": "literature-mepact-dops-popc-liposomal-mifamurtide",
        "kind": "recipe",
        "name": "Mepact-type DOPS/POPC liposomal mifamurtide",
        "category": "Liposome",
        "tags": [
          "Liposome",
          "Literature recipe"
        ],
        "steps": [],
        "materials": [
          {
            "name": "DOPS",
            "detail": "Dioleoyl phosphatidylserine; 30 mol%"
          },
          {
            "name": "POPC",
            "detail": "1-palmitoyl-2-oleoyl phosphatidylcholine; 70 mol%"
          },
          {
            "name": "MTP-PE",
            "detail": "Mifamurtide; 4 mg per vial"
          }
        ],
        "tables": [
          {
            "id": "composition",
            "name": "Anionic liposome composition",
            "header": [
              "Component / parameter",
              "Value",
              "Context"
            ],
            "rows": [
              [
                "DOPS",
                "30 mol%",
                "Anionic phosphatidylserine lipid"
              ],
              [
                "POPC",
                "70 mol%",
                "Phosphatidylcholine lipid"
              ],
              [
                "Total lipid",
                "1 g per vial",
                "Reviewed vial composition"
              ],
              [
                "MTP-PE",
                "4 mg per vial",
                "Mifamurtide"
              ],
              [
                "Vesicle form",
                "Multilamellar vesicles <100 nm",
                "Reviewed formulation"
              ]
            ]
          }
        ],
        "tableChoices": {},
        "author": "Listen Step",
        "origin": {
          "type": "curated-literature",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5489929/",
          "reviewedAt": "2026-11-09"
        },
        "source": {
          "citation": "Bulbake U et al. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9, 12 (2017).",
          "doi": "10.3390/pharmaceutics9020012",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5489929/",
          "locator": "Table 1 and Section 3.1.5, Mepact"
        },
        "review": {
          "status": "source-values-checked",
          "reviewedAt": "2026-11-09",
          "scope": "Literature composition only, not clinical manufacturing, immunotherapy or administration guidance."
        },
        "createdAt": 1794182400000,
        "updatedAt": 1794182400000
      }
    }
  ],
  "materials": [
    {
      "name": "DOPS",
      "detail": "Dioleoyl phosphatidylserine; 30 mol%"
    },
    {
      "name": "POPC",
      "detail": "1-palmitoyl-2-oleoyl phosphatidylcholine; 70 mol%"
    },
    {
      "name": "MTP-PE",
      "detail": "Mifamurtide; 4 mg per vial"
    }
  ],
  "source": {
    "citation": "Bulbake U et al. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9, 12 (2017).",
    "doi": "10.3390/pharmaceutics9020012",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5489929/",
    "locator": "Table 1 and Section 3.1.5, Mepact"
  },
  "review": {
    "status": "source-values-checked",
    "reviewedAt": "2026-11-09"
  }
}
